Imjudo (tremelimumab) Patient Assistance Program
Don’t let the high cost of brand anti-CTLA-4 immunotherapy disrupt your liver cancer treatment. We help eligible patients access Imjudo (tremelimumab-actl IV infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Imjudo (tremelimumab) is FDA-approved (in combination with durvalumab/Imfinzi) for adults with unresectable hepatocellular carcinoma (HCC — liver cancer); and (with Imfinzi and platinum-based chemotherapy) for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations. Anti-CTLA-4 monoclonal antibody immune checkpoint inhibitor — enhances T-cell activation.
- Without assistance, Imjudo costs commonly run approximately $22,000+ per infusion.
- Through AffordMyPrescriptions, qualifying patients can access Imjudo for a flat $69.95 per month.
- Other CTLA-4 inhibitors: Yervoy (ipilimumab — brand; multiple cancer indications). Anti-PD-L1/PD-1 inhibitors: Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab), Bavencio, Libtayo, Jemperli, Loqtorzi. Combination immunotherapy strategies (Imjudo+Imfinzi, Yervoy+Opdivo) leverage complementary immune activation. Liver cancer therapy: sorafenib (Nexavar generic), lenvatinib (Lenvima brand), cabozantinib, atezolizumab+bevacizumab. Oncology specialty required.
What is Imjudo Prescription Assistance Program?
The Imjudo Patient Assistance Program helps eligible patients access Imjudo for liver cancer or NSCLC at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but involves detailed applications, oncology coordination, and renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Imjudo PAP enrollment for a flat $69.95 per month — so you never face a gap in your Imjudo immunotherapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Imjudo enrollment — so you never face a gap in your combination immunotherapy for liver cancer or NSCLC.
Pharmacy Price Comparison
- Without assistance, Imjudo costs tens of thousands per infusion. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Sorafenib generic (HCC alt) | ~$500/mo | Generic TKI alt for HCC |
| Cancer center pharmacy | ~$23,000/infusion | Save substantially |
| Community oncology | ~$22,000/infusion | Save substantially |
| Hospital outpatient | ~$22,500/infusion | Save substantially |
| 340B-eligible institution | ~$18,000/infusion | Save substantially |
| Yervoy (alt CTLA-4) | ~$25,000/dose | Alt CTLA-4 inhibitor |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Imjudo — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Imjudo Prescription Program?
The Imjudo Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. HCC and NSCLC combination immunotherapy strategies leverage complementary immune activation. Comprehensive oncology and immunotherapy-toxicity management are essential.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Imjudo assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Imjudo is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Imjudo:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $22,000–$23,000/infusion even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Imjudo assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Imjudo Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Imjudo:
Imjudo (tremelimumab) is an anti-CTLA-4 monoclonal antibody immune checkpoint inhibitor — releasing inhibition on T-cells to enhance anti-tumor immunity. Approved in combination with anti-PD-L1 durvalumab (Imfinzi) for unresectable HCC (STRIDE regimen) and NSCLC.
How It Works:
Cancer cells evade immune destruction via immune checkpoint pathways — CTLA-4 (on T-cells) and PD-1/PD-L1 (tumor and immune cells) suppress T-cell activation. Blocking these checkpoints releases T-cells to attack cancer. Combination CTLA-4 + PD-L1 blockade leverages complementary mechanisms: CTLA-4 blockade enhances T-cell priming (mainly in lymph nodes); PD-L1 blockade releases T-cell activity in the tumor microenvironment. Tremelimumab is an anti-CTLA-4 monoclonal antibody. Combined with durvalumab (anti-PD-L1), Imjudo delivers dual checkpoint blockade for HCC (STRIDE regimen: a single priming dose of Imjudo plus continuous Imfinzi). It is also approved with Imfinzi + platinum chemotherapy for metastatic NSCLC without actionable driver mutations. Immune-related adverse events (irAEs) require expert management.
Form and Use:
Imjudo IV infusion. For HCC (STRIDE regimen): a single priming dose of Imjudo 300 mg IV followed by Imfinzi every 4 weeks continuously. For NSCLC: multiple Imjudo doses with Imfinzi + chemotherapy per protocol. Given at a cancer center or infusion suite. Immunotherapy toxicity monitoring is essential.
Generic Availability:
No generic Imjudo. Yervoy (ipilimumab — brand) is the other approved anti-CTLA-4. Anti-PD-1/PD-L1 inhibitors: Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab), Bavencio (avelumab), Libtayo (cemiplimab), Jemperli (dostarlimab), Loqtorzi (toripalimab). For HCC alternatives: sorafenib generic, lenvatinib (Lenvima brand), cabozantinib, atezolizumab (Tecentriq) + bevacizumab (Avastin or biosimilars), Yervoy+Opdivo, regorafenib (post-progression). For NSCLC: pembrolizumab (Keytruda) commonly first-line combo, plus many other options. Comprehensive oncology consultation for an individualized approach.
Warnings:
Immune-related adverse events (immune checkpoint inhibitor toxicities — can affect any organ; higher rate with CTLA-4 + PD-L1 combination than PD-L1 monotherapy — colitis, hepatitis, pneumonitis, endocrinopathies including hypophysitis, thyroid dysfunction, adrenal insufficiency, type 1 diabetes; nephritis; dermatitis including SJS/TEN; myocarditis rare but potentially fatal; myositis; neurologic events; and others — manage per checkpoint inhibitor toxicity guidelines with corticosteroids and/or other immunosuppressants; permanent discontinuation for severe irAEs), infusion reactions, embryo-fetal toxicity. Other: fatigue, decreased appetite, diarrhea, rash, pruritus. Oncology follow-up and irAE surveillance essential. A multidisciplinary irAE management team is helpful.
FAQ (Frequently Asked Questions)
How much does Imjudo cost without insurance?
$22,000–$23,000 per infusion at cancer centers. The HCC STRIDE regimen involves a single priming Imjudo dose plus ongoing Imfinzi; NSCLC involves multiple Imjudo doses. Total treatment costs vary. Patient Assistance Programs are essential.
What is the STRIDE regimen for HCC?
STRIDE (Single Tremelimumab Regular Interval Durvalumab) is a novel dosing schedule for unresectable hepatocellular carcinoma: a single priming dose of Imjudo (tremelimumab) 300 mg IV plus continuous Imfinzi (durvalumab) every 4 weeks. It provides dual checkpoint blockade with reduced CTLA-4 toxicity vs full-dose CTLA-4 dosing, and established improved overall survival vs sorafenib in the HIMALAYA trial.
How is Imjudo different from Yervoy (ipilimumab)?
Both are anti-CTLA-4 monoclonal antibodies, with a different sponsor and slightly different molecule/dosing. Yervoy has more approved indications (melanoma, renal cell, colorectal MSI-H, NSCLC, mesothelioma, esophageal, HCC; often combined with nivolumab/Opdivo). Imjudo is combined with durvalumab (Imfinzi) for HCC (STRIDE) and NSCLC. Clinical roles depend on tumor type and combination partner.
What are immune-related adverse events (irAEs)?
Immune checkpoint inhibitors release the immune system to fight cancer but can also cause immune-mediated inflammation of any organ — irAEs. Any organ can be affected (colon, liver, lung, endocrine glands, kidney, skin, heart, muscle, nerves). Combination CTLA-4 + PD-L1 immunotherapy carries a higher irAE rate than monotherapy. Prompt recognition and management with corticosteroids or other immunosuppressants is critical.
How long is Imjudo therapy?
For HCC STRIDE: Imjudo is a single priming dose; Imfinzi continues every 4 weeks until progression or unacceptable toxicity. For NSCLC: multiple Imjudo doses with Imfinzi + chemotherapy per protocol. Discuss expectations with your oncology team.
Take Control of Your Medication Costs
Combination immunotherapy transformed HCC and NSCLC outcomes. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.